{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T00:16:44Z","timestamp":1794874604869,"version":"4.9.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31830094"],"award-info":[{"award-number":["31830094"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31902215"],"award-info":[{"award-number":["31902215"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32272939"],"award-info":[{"award-number":["32272939"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["SWU120064"],"award-info":[{"award-number":["SWU120064"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Natural Science Foundation of Chongqing, China","award":["cstc2021jcyj-cxtt0017"],"award-info":[{"award-number":["cstc2021jcyj-cxtt0017"]}]},{"name":"High-level Talents Program of Southwest University","award":["SWURC2021001"],"award-info":[{"award-number":["SWURC2021001"]}]},{"name":"China Agriculture Research System of MOF and MARA","award":["CARS-18-ZJ0102"],"award-info":[{"award-number":["CARS-18-ZJ0102"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Parkinson\u2019s disease (PD) is the second most common neurodegenerative disease in middle-aged and elderly populations, whereas there is no cure for PD so far. Novel animal models and medications await development to elucidate the aetiology of PD and attenuate the symptoms, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), was used in the current study to establish a PD pathologic model in silkworms. The time required to complete specific behaviours was recorded. Dopamine content was detected by ultra-performance liquid chromatography (UPLC). The activity of insect tyrosine hydroxylase (TH) was determined using a double-antibody sandwich method. Oxidative stress was assessed by changes in antioxidant enzyme activity and the content of oxidative products.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      MPTP-treated silkworms were characterized by impaired motor ability, reduced dopamine content, and elevated oxidative stress level. The expression of TH, a dopamine biosynthetic enzyme within dopaminergic neurons in the brain, was significantly reduced, indicating that dopaminergic neurons were damaged. Moreover, MPTP-induced motility impairment and reduced dopamine level in the silkworm PD model could be rescued after feeding a combination of levodopa (L-dopa [LD]) and carbidopa (CD). MPTP-induced oxidative damage was also alleviated, in ways consistent with other PD animal models. Interestingly, administration of\n                      <jats:italic>Lycium barbarum<\/jats:italic>\n                      polysaccharide (LBP) improved the motor ability, dopamine level, and TH activity, and the oxidative damage was concomitantly reduced in the silkworm PD model.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provides a promising animal model for elucidating the pathogenesis of PD, as well as a relevant preliminary drug screening (e.g., LBP) and evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-022-02621-9","type":"journal-article","created":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T20:02:34Z","timestamp":1666900954000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Lycium barbarum polysaccharide improves dopamine metabolism and symptoms in an MPTP-induced model of Parkinson\u2019s disease"],"prefix":"10.1186","volume":"20","author":[{"given":"Jiangbo","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiquan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunzhu","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0215-2177","authenticated-orcid":false,"given":"Fangyin","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"key":"2621_CR1","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/jnnp.2007.131045","volume":"79","author":"J Jankovic","year":"2008","unstructured":"Jankovic J. Parkinson\u2019s disease: clinical features and diagnosis. J Neurol Neurosur Ps. 2008;79:368\u201376. https:\/\/doi.org\/10.1136\/jnnp.2007.131045.","journal-title":"J Neurol Neurosur Ps"},{"issue":"1","key":"2621_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1136\/practneurol-2014-000849","volume":"15","author":"K Ali","year":"2015","unstructured":"Ali K, Morris HR. Parkinson\u2019s disease: chameleons and mimics. Pract Neurol. 2015;15(1):14\u201325. https:\/\/doi.org\/10.1136\/practneurol-2014-000849.","journal-title":"Pract Neurol"},{"issue":"9","key":"2621_CR3","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1001\/archneur.64.9.1242","volume":"64","author":"L Gilberto","year":"2007","unstructured":"Gilberto L. The relationship of Parkinson disease with aging. Arch Neurol. 2007;64(9):1242\u20136. https:\/\/doi.org\/10.1001\/archneur.64.9.1242.","journal-title":"Arch Neurol"},{"issue":"s1","key":"2621_CR4","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.3233\/JPD-181474","volume":"8","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Sherer T, Okun M, Bloem BR. The emerging evidence of the Parkinson pandemic. J Parkinsons Dis. 2018;8(s1):S3\u20138. https:\/\/doi.org\/10.3233\/JPD-181474.","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"2621_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1001\/jamaneurol.2017.3299","volume":"5","author":"ER Dorsey","year":"2018","unstructured":"Dorsey ER, Bloem BR. The Parkinson pandemic-A call to action. JAMA Neurol. 2018;5(1):9\u201310. https:\/\/doi.org\/10.1001\/jamaneurol.2017.3299.","journal-title":"JAMA Neurol"},{"key":"2621_CR6","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1016\/j.metabol.2014.10.030","volume":"301","author":"DB Miller","year":"2015","unstructured":"Miller DB, O\u2019Callaghan JP. Biomarkers of Parkinson\u2019s disease: present and future. Metabolism. 2015;301:S40\u201360. https:\/\/doi.org\/10.1016\/j.metabol.2014.10.030.","journal-title":"Metabolism."},{"key":"2621_CR7","doi-asserted-by":"publisher","first-page":"9730467","DOI":"10.1155\/2016\/9730467","volume":"2016","author":"HJ Olgu\u00edn","year":"2015","unstructured":"Olgu\u00edn HJ, Guzm\u00e1n DC, Garc\u00eda EH, Mej\u00eda GB. The role of dopamine and its dysfunction as a consequence of oxidative stress. Oxid Med Cell Longev. 2015;2016:9730467. https:\/\/doi.org\/10.1155\/2016\/9730467.","journal-title":"Oxid Med Cell Longev"},{"issue":"4","key":"2621_CR8","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/s1353-8020(02)00048-2","volume":"9","author":"J Carr","year":"2003","unstructured":"Carr J, de la Fuente-Fernandez R, Schulzer M, Mak E, Calne SM, Calne DB. Familial and sporadic Parkinson\u2019s disease usually display the same clinical features. Parkinsonism Relat Disord. 2003;9(4):201\u20134. https:\/\/doi.org\/10.1016\/s1353-8020(02)00048-2.","journal-title":"Parkinsonism Relat Disord"},{"issue":"5","key":"2621_CR9","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s11910-005-0064-6","volume":"5","author":"AJ Lewthwaite","year":"2005","unstructured":"Lewthwaite AJ, Nicholl DJ. Genetics of parkinsonism. Curr Neurol Neurosci Rep. 2005;5(5):397\u2013404. https:\/\/doi.org\/10.1007\/s11910-005-0064-6.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"1","key":"2621_CR10","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1038\/s41467-021-22113-3","volume":"12","author":"S Kim","year":"2021","unstructured":"Kim S, Wong YC, Gao F, Krainc D. Dysregulation of mitochondria-lysosome contacts by GBA1 dysfunction in dopaminergic neuronal models of Parkinson's disease. Nat Commun. 2021;12(1):1807. https:\/\/doi.org\/10.1038\/s41467-021-22113-3.","journal-title":"Nat Commun"},{"issue":"1","key":"2621_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3109\/10715762.2010.512040","volume":"45","author":"S Grimm","year":"2011","unstructured":"Grimm S, Hoehn A, Davies KJ, Grune T. Protein oxidative modifications in the ageing brain: consequence for the onset of neurodegenerative disease. Free Radic Res. 2011;45(1):73\u201388. https:\/\/doi.org\/10.3109\/10715762.2010.512040.","journal-title":"Free Radic Res"},{"key":"2621_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.793804","volume":"12","author":"F Luo","year":"2021","unstructured":"Luo F, Ye M, Lv T, Hu B, Chen J, Yan J, et al. Efficacy of cognitive behavioral therapy on mood disorders, sleep, fatigue, and quality of life in Parkinson\u2019s disease: a systematic review and meta-analysis. Front Psych. 2021;12:793804. https:\/\/doi.org\/10.3389\/fpsyt.2021.793804.","journal-title":"Front Psych"},{"issue":"12","key":"2621_CR13","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S1474-4422(04)00934-2","volume":"3","author":"BL Walter","year":"2004","unstructured":"Walter BL, Vitek JL. Surgical treatment for Parkinson\u2019s disease. Lancet Neurol. 2004;3(12):719\u201328. https:\/\/doi.org\/10.1016\/S1474-4422(04)00934-2.","journal-title":"Lancet Neurol"},{"issue":"1","key":"2621_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1006\/exnr.1996.6387","volume":"144","author":"TB Freeman","year":"1997","unstructured":"Freeman TB. From transplants to gene therapy for Parkinson\u2019s disease. Exp Neurol. 1997;144(1):47\u201350. https:\/\/doi.org\/10.1006\/exnr.1996.6387.","journal-title":"Exp Neurol"},{"issue":"2","key":"2621_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41583-019-0257-7","volume":"21","author":"M Parmar","year":"2020","unstructured":"Parmar M, Grealish S, Henchcliffe C. The future of stem cell therapies for Parkinson disease. Nat Rev Neurosci. 2020;21(2):103\u201315. https:\/\/doi.org\/10.1038\/s41583-019-0257-7.","journal-title":"Nat Rev Neurosci"},{"key":"2621_CR16","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.brainresbull.2020.12.017","volume":"168","author":"CL Zhang","year":"2021","unstructured":"Zhang CL, Han QW, Chen NH, Yuan YH. Research on developing drugs for Parkinson\u2019s disease. Brain Res Bull. 2021;168:100\u20139. https:\/\/doi.org\/10.1016\/j.brainresbull.2020.12.017.","journal-title":"Brain Res Bull"},{"issue":"2","key":"2621_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.14802\/jmd.20147","volume":"14","author":"SR Kim","year":"2021","unstructured":"Kim SR, Kim JY, Kim HY, So HY, Chung SJ. Factors associated with medication beliefs in patients with Parkinson\u2019s disease: a cross-sectional study. J Mov Disord. 2021;14(2):133\u201343. https:\/\/doi.org\/10.14802\/jmd.20147.","journal-title":"J Mov Disord"},{"issue":"1","key":"2621_CR18","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/mds.26082","volume":"30","author":"PA LeWitt","year":"2015","unstructured":"LeWitt PA. Levodopa therapy for Parkinson\u2019s disease: pharmacokinetics and pharmacodynamics. Mov Disord. 2015;30(1):64\u201372. https:\/\/doi.org\/10.1002\/mds.26082.","journal-title":"Mov Disord"},{"issue":"1","key":"2621_CR19","first-page":"37","volume":"89","author":"JA Borovac","year":"2016","unstructured":"Borovac JA. Side effects of a dopamine agonist therapy for Parkinson\u2019s disease: a mini-review of clinical pharmacology. Yale J Biol Med. 2016;89(1):37\u201347.","journal-title":"Yale J Biol Med"},{"issue":"2","key":"2621_CR20","first-page":"39","volume":"2","author":"DR Brocks","year":"1999","unstructured":"Brocks DR. Anticholinergic drugs used in Parkinson\u2019s disease: an overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharm Sci. 1999;2(2):39\u201346.","journal-title":"J Pharm Pharm Sci"},{"issue":"14","key":"2621_CR21","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1212\/WNL.0b013e31824e8f0d","volume":"78","author":"G Hubsher","year":"2012","unstructured":"Hubsher G, Haider M, Okun MS. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology. 2012;78(14):1096\u20139. https:\/\/doi.org\/10.1212\/WNL.0b013e31824e8f0d.","journal-title":"Neurology."},{"issue":"4","key":"2621_CR22","doi-asserted-by":"publisher","first-page":"425","DOI":"10.2174\/1871527316666170124165222","volume":"16","author":"L Dezsi","year":"2017","unstructured":"Dezsi L, Vecsei L. Monoamine oxidase B inhibitors in Parkinson\u2019s disease. CNS Neurol Disord Drug Targets. 2017;16(4):425\u201339. https:\/\/doi.org\/10.2174\/1871527316666170124165222.","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"4","key":"2621_CR23","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00702-018-1952-7","volume":"126","author":"JPM Finberg","year":"2019","unstructured":"Finberg JPM. Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson\u2019s disease. J Neural Transm (Vienna). 2019;126(4):433\u201348. https:\/\/doi.org\/10.1007\/s00702-018-1952-7.","journal-title":"J Neural Transm (Vienna)"},{"key":"2621_CR24","doi-asserted-by":"publisher","first-page":"1599477","DOI":"10.1155\/2021\/1599477","volume":"2021","author":"H Ogura","year":"2021","unstructured":"Ogura H, Nakagawa R, Ishido M, Yoshinaga Y, Watanabe J, Kurihara K, et al. Evaluation of motor complications in Parkinson\u2019s disease: understanding the perception gap between patients and physicians. Parkinsons Dis. 2021;2021:1599477. https:\/\/doi.org\/10.1155\/2021\/1599477.","journal-title":"Parkinsons Dis"},{"issue":"4","key":"2621_CR25","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1111\/ene.15234","volume":"29","author":"CC Wang","year":"2022","unstructured":"Wang CC, Wu TL, Lin FJ, Tai CH, Lin CH, Wu RM. Amantadine treatment and delayed onset of levodopa-induced dyskinesia in patients with early Parkinson\u2019s disease. Eur J Neurol. 2022;29(4):1044\u201355. https:\/\/doi.org\/10.1111\/ene.15234.","journal-title":"Eur J Neurol"},{"issue":"2","key":"2621_CR26","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1001\/jamaneurol.2021.4736","volume":"79","author":"R Gray","year":"2022","unstructured":"Gray R, Patel S, Ives N, Rick C, Woolley R, Muzerengi S, et al. Long-term effectiveness of adjuvant treatment with catechol-O-methyltransferase or monoamine oxidase B inhibitors compared with dopamine agonists among patients with Parkinson disease uncontrolled by Levodopa therapy: The PD med randomized clinical trial. JAMA Neurol. 2022;79(2):131\u201340. https:\/\/doi.org\/10.1001\/jamaneurol.2021.4736.","journal-title":"JAMA Neurol"},{"issue":"1","key":"2621_CR27","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00702-021-02447-4","volume":"129","author":"BL Santos-Lobato","year":"2022","unstructured":"Santos-Lobato BL, Bortolanza M, Pinheiro LC, Batalhao ME, Pimental AV, Capellari-Carnio, et al. Levodopa-induced dyskinesias in Parkinson\u2019s disease increase cerebrospinal fluid nitric oxide metabolites\u2019levels. J Neural Transm (Vienna). 2022;129(1):55\u201363. https:\/\/doi.org\/10.1007\/s00702-021-02447-4.","journal-title":"J Neural Transm (Vienna)"},{"issue":"9996","key":"2621_CR28","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE. Parkinson\u2019s disease. Lancet. 2015;386(9996):896\u2013912. https:\/\/doi.org\/10.1016\/S0140-6736(14)61393-3.","journal-title":"Lancet."},{"issue":"8","key":"2621_CR29","doi-asserted-by":"publisher","first-page":"502","DOI":"10.2174\/1389202914666131210205839","volume":"14","author":"A Oczkowska","year":"2013","unstructured":"Oczkowska A, Kozubski W, Lianeri M, Dorszewska J. Mutations in PRKN and SNCA genes important for the progress of Parkinson\u2019s disease. Curr Genomics. 2013;14(8):502\u201317. https:\/\/doi.org\/10.2174\/1389202914666131210205839.","journal-title":"Curr Genomics"},{"issue":"2","key":"2621_CR30","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1007\/s12035-018-1148-z","volume":"56","author":"S Bastias-Candia","year":"2019","unstructured":"Bastias-Candia S, Zolezzi JM, Inestrosa NC. Revisiting the paraquat-induced sporadic Parkinson\u2019s disease-like model. Mol Neurobiol. 2019;56(2):1044\u201355. https:\/\/doi.org\/10.1007\/s12035-018-1148-z.","journal-title":"Mol Neurobiol"},{"key":"2621_CR31","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jchemneu.2018.12.011","volume":"96","author":"PC Leal","year":"2019","unstructured":"Leal PC, Bispo JMM, Engelberth R, KDDA S, Meurer YR, Ribeiro AM, et al. Serotonergic dysfunction in a model of parkinsonism induced by reserpine. J Chem Neuroanat. 2019;96:73\u20138. https:\/\/doi.org\/10.1016\/j.jchemneu.2018.12.011.","journal-title":"J Chem Neuroanat"},{"issue":"3-4","key":"2621_CR32","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/BF03033565","volume":"11","author":"N Simola","year":"2007","unstructured":"Simola N, Morelli M, Carta AR. The 6-hydroxydopamine model of Parkinson\u2019s disease. Neurotox Res. 2007;11(3-4):151\u201367. https:\/\/doi.org\/10.1007\/BF03033565.","journal-title":"Neurotox Res"},{"issue":"34","key":"2621_CR33","doi-asserted-by":"publisher","first-page":"10756","DOI":"10.1523\/JNEUROSCI.23-34-10756.2003","volume":"23","author":"TB Sherer","year":"2003","unstructured":"Sherer TB, Betarbet R, Testa CM, Seo BB, Richardson JR, Kim JH, et al. Mechanism of toxicity in rotenone models of Parkinson\u2019s disease. J Neurosci. 2003;23(34):10756\u201364. https:\/\/doi.org\/10.1523\/JNEUROSCI.23-34-10756.2003.","journal-title":"J Neurosci"},{"issue":"2","key":"2621_CR34","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/s0301-0082(01)00003-x","volume":"65","author":"D Blum","year":"2001","unstructured":"Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson\u2019s disease. Prog Neurobiol. 2001;65(2):135\u201372. https:\/\/doi.org\/10.1016\/s0301-0082(01)00003-x.","journal-title":"Prog Neurobiol"},{"key":"2621_CR35","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.bbr.2015.04.037","volume":"290","author":"M Santana","year":"2015","unstructured":"Santana M, Palmer T, Simplicio H, Fuentes R, Petersson P. Characterization of long-term motor deficits in the 6-OHDA model of Parkinson\u2019s disease in the common marmoset. Behav Brain Res. 2015;290:90\u2013101. https:\/\/doi.org\/10.1016\/j.bbr.2015.04.037.","journal-title":"Behav Brain Res"},{"issue":"7","key":"2621_CR36","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3109\/10408444.2012.680431","volume":"42","author":"N Xiong","year":"2012","unstructured":"Xiong N, Long X, Xiong J, Jia M, Chen C, Huang J, et al. Mitochondrial complex I inhibitor rotenone-induced toxicity and its potential mechanisms in Parkinson\u2019s disease models. Crit Rev Toxicol. 2012;42(7):613\u201332. https:\/\/doi.org\/10.3109\/10408444.2012.680431.","journal-title":"Crit Rev Toxicol"},{"issue":"4","key":"2621_CR37","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/bpa.12253","volume":"25","author":"AH Leao","year":"2015","unstructured":"Leao AH, Sarmento-Silva AJ, Santos JR, Ribeiro AM, Silva RH. Molecular, neurochemical, and behavioral hallmarks of reserpine as a model for Parkinson\u2019s disease: new perspectives to a long-standing model. Brain Pathol. 2015;25(4):377\u201390. https:\/\/doi.org\/10.1111\/bpa.12253.","journal-title":"Brain Pathol"},{"issue":"6","key":"2621_CR38","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.tips.2017.03.010","volume":"38","author":"S Schildknecht","year":"2017","unstructured":"Schildknecht S, Di Monte DA, Pape R, Tieu K, Leist M. Tipping points and endogenous determinants of nigrostriatal degeneration by MPTP. Trends Pharmacol Sci. 2017;38(6):541\u201355. https:\/\/doi.org\/10.1016\/j.tips.2017.03.010.","journal-title":"Trends Pharmacol Sci"},{"key":"2621_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104792","volume":"140","author":"A Narmashiri","year":"2022","unstructured":"Narmashiri A, Abbaszadeh M, Ghazizadeh A. The effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on the cognitive and motor functions in rodents: a systematic review and meta-analysis. Neurosci Biobehav Rev. 2022;140:104792. https:\/\/doi.org\/10.1016\/j.neubiorev.2022.104792.","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"2621_CR40","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/mdc3.13344","volume":"9","author":"S AlShimemeri","year":"2021","unstructured":"AlShimemeri S, Di Luca DG, Fox SH. MPTP parkinsonism and implications for understanding Parkinson\u2019s disease. Mov Disord Clin Pract. 2021;9(1):42\u20137. https:\/\/doi.org\/10.1002\/mdc3.13344.","journal-title":"Mov Disord Clin Pract"},{"issue":"4","key":"2621_CR41","first-page":"644","volume":"14","author":"DG Graham","year":"1978","unstructured":"Graham DG, Tiffany SM, Bell WR, Gutknecht WF. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol. 1978;14(4):644\u201353.","journal-title":"Mol Pharmacol"},{"issue":"11","key":"2621_CR42","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1039\/c3np70031c","volume":"30","author":"A Argyropoulou","year":"2013","unstructured":"Argyropoulou A, Aligiannis N, Trougakos IP, Skaltsounis AL. Natural compounds with anti-ageing activity. Nat Prod Rep. 2013;30(11):1412\u201337. https:\/\/doi.org\/10.1039\/c3np70031c.","journal-title":"Nat Prod Rep"},{"issue":"11","key":"2621_CR43","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1111\/bph.13631","volume":"174","author":"CY Shen","year":"2017","unstructured":"Shen CY, Jiang JG, Yang L, Wang DW, Zhu W. Anti-ageing active ingredients from herbs and nutraceuticals used in traditional Chinese medicine: pharmacological mechanisms and implications for drug discovery. Br J Pharmacol. 2017;174(11):1395\u2013425. https:\/\/doi.org\/10.1111\/bph.13631.","journal-title":"Br J Pharmacol"},{"issue":"20","key":"2621_CR44","first-page":"2760","volume":"17","author":"HB Wang","year":"2013","unstructured":"Wang HB, Li YX, Hao YJ, Wang TF, Lei Z, Wu Y, et al. Neuroprotective effects of LBP on brain ischemic reperfusion neurodegeneration. Eur Rev Med Pharmacol Sci. 2013;17(20):2760\u20135.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"4","key":"2621_CR45","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1007\/s11064-018-2499-6","volume":"43","author":"X Wang","year":"2018","unstructured":"Wang X, Pang L, Zhang Y, Xu J, Ding D, Yang T, et al. Lycium barbarum Polysaccharide promotes nigrostriatal dopamine function by modulating PTEN\/AKT\/mTOR pathway in a Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) murine model of Parkinson\u2019s disease. Neurochem Res. 2018;43(4):938\u201347. https:\/\/doi.org\/10.1007\/s11064-018-2499-6.","journal-title":"Neurochem Res"},{"issue":"5","key":"2621_CR46","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.3892\/etm.2017.5127","volume":"14","author":"S Cao","year":"2017","unstructured":"Cao S, Du J, Hei Q. Lycium barbarum polysaccharide protects against neurotoxicity via the Nrf2-HO-1 pathway. Exp Ther Med. 2017;14(5):4919\u201327. https:\/\/doi.org\/10.3892\/etm.2017.5127.","journal-title":"Exp Ther Med"},{"issue":"14","key":"2621_CR47","doi-asserted-by":"publisher","first-page":"4606","DOI":"10.1167\/iovs.19-27886","volume":"60","author":"Y Lakshmanan","year":"2019","unstructured":"Lakshmanan Y, Wong FSY, Zuo B, So KF, Bui BV, Chan HH. Posttreatment intervention with Lycium barbarum polysaccharides is neuroprotective in a Rat model of chronic ocular hypertension. Invest Ophthalmol Vis Sci. 2019;60(14):4606\u201318. https:\/\/doi.org\/10.1167\/iovs.19-27886.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"2621_CR48","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/mds.23732","volume":"26","author":"AH Schapira","year":"2011","unstructured":"Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson\u2019s disease. Mov Disord. 2011;26(6):1049\u201355. https:\/\/doi.org\/10.1002\/mds.23732.","journal-title":"Mov Disord"},{"issue":"005","key":"2621_CR49","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1744-7917.2008.00227.x","volume":"15","author":"GH Wang","year":"2008","unstructured":"Wang GH, Xia QY, Cheng DJ, Duan J, Zhao P, Chen J, et al. Reference genes identified in the silkworm Bombyx mori during metamorphism based on oligonucleotide microarray and confirmed by Qrt-PCR. Insect Sci. 2008;15(005):405\u201313. https:\/\/doi.org\/10.1111\/j.1744-7917.2008.00227.x.","journal-title":"Insect Sci"},{"key":"2621_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.612476","volume":"9","author":"W Li","year":"2021","unstructured":"Li W, Fu Y, Halliday GM, Sue CM. PARK genes link mitochondrial dysfunction and alpha-synuclein pathology in sporadic Parkinson\u2019s disease. Front Cell Dev Biol. 2021;9:612476. https:\/\/doi.org\/10.3389\/fcell.2021.612476.","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"2621_CR51","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13031","volume":"18","author":"BG Trist","year":"2019","unstructured":"Trist BG, Hare DJ, Double KL. Oxidative stress in the aging substantia nigra and the etiology of Parkinson\u2019s disease. Aging Cell. 2019;18(6):e13031. https:\/\/doi.org\/10.1111\/acel.13031.","journal-title":"Aging Cell"},{"issue":"3","key":"2621_CR52","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s12017-016-8393-y","volume":"18","author":"X Xing","year":"2016","unstructured":"Xing X, Liu F, Xiao J, So KF. Neuro-protective mechanisms of Lycium barbarum. Neuromolecular Med. 2016;18(3):253\u201363. https:\/\/doi.org\/10.1007\/s12017-016-8393-y.","journal-title":"Neuromolecular Med"},{"issue":"6","key":"2621_CR53","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1142\/S0192415X13500900","volume":"41","author":"AR Im","year":"2013","unstructured":"Im AR, Kim YH, Uddin MR, Chae S, Lee HW, Kim YS, et al. Neuroprotective effects of Lycium chinense miller against rotenone-induced neurotoxicity in PC12 cells. Am J Chin Med. 2013;41(6):1343\u201359. https:\/\/doi.org\/10.1142\/S0192415X13500900.","journal-title":"Am J Chin Med"},{"issue":"1","key":"2621_CR54","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3390\/molecules20010293","volume":"20","author":"K Gao","year":"2014","unstructured":"Gao K, Liu M, Cao J, Yao M, Lu Y, Li J, et al. Protective effects of Lycium barbarum polysaccharide on 6-OHDA-induced apoptosis in PC12 cells through the ROS-NO pathway. Molecules. 2014;20(1):293\u2013308. https:\/\/doi.org\/10.3390\/molecules20010293.","journal-title":"Molecules."},{"issue":"10","key":"2621_CR55","doi-asserted-by":"publisher","first-page":"18102","DOI":"10.3390\/ijms151018102","volume":"15","author":"Z Zhang","year":"2014","unstructured":"Zhang Z, Teng X, Chen M, Li F. Orthologs of human disease associated genes and RNAi analysis of silencing insulin receptor gene in Bombyx mori. Int J Mol Sci. 2014;15(10):18102\u201316. https:\/\/doi.org\/10.3390\/ijms151018102.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2621_CR56","doi-asserted-by":"publisher","DOI":"10.1098\/rsos.191888","volume":"7","author":"G Jiang","year":"2020","unstructured":"Jiang G, Song J, Hu H, Tong X, Dai F. Evaluation of the silkworm lemon mutant as an invertebrate animal model for human sepiapterin reductase deficiency. R Soc Open Sci. 2020;7(3):191888. https:\/\/doi.org\/10.1098\/rsos.191888.","journal-title":"R Soc Open Sci"},{"issue":"3","key":"2621_CR57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018292","volume":"6","author":"Y Matsumoto","year":"2011","unstructured":"Matsumoto Y, Sumiya E, Sugita T, Sekimizu K. An invertebrate hyperglycemic model for the identification of anti-diabetic drugs. PLoS One. 2011;6(3):e18292. https:\/\/doi.org\/10.1371\/journal.pone.0018292.","journal-title":"PLoS One"},{"key":"2621_CR58","doi-asserted-by":"publisher","first-page":"10722","DOI":"10.1038\/srep10722","volume":"5","author":"Y Matsumoto","year":"2015","unstructured":"Matsumoto Y, Ishii M, Hayashi Y, Miyazaki S, Sugita T, Sumiya E, et al. Diabetic silkworms for evaluation of therapeutically effective drugs against type II diabetes. Sci Rep. 2015;5:10722. https:\/\/doi.org\/10.1038\/srep10722.","journal-title":"Sci Rep"},{"issue":"1","key":"2621_CR59","doi-asserted-by":"publisher","first-page":"19","DOI":"10.5582\/ddt.2016.01017","volume":"10","author":"Y Matsumoto","year":"2016","unstructured":"Matsumoto Y, Sekimizu K. Evaluation of anti-diabetic drugs by using silkworm, Bombyx mori. Drug Discov Ther. 2016;10(1):19\u201323. https:\/\/doi.org\/10.5582\/ddt.2016.01017.","journal-title":"Drug Discov Ther"},{"key":"2621_CR60","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1673\/031.012.0401","volume":"12","author":"X Zhang","year":"2012","unstructured":"Zhang X, Xue R, Cao G, Pan Z, Zheng X, Gong C. Silkworms can be used as an animal model to screen and evaluate gouty therapeutic drugs. J Insect Sci. 2012;12:4. https:\/\/doi.org\/10.1673\/031.012.0401.","journal-title":"J Insect Sci"},{"key":"2621_CR61","doi-asserted-by":"publisher","first-page":"12308","DOI":"10.1038\/srep12308","volume":"5","author":"H Nie","year":"2015","unstructured":"Nie H, Cheng T, Huang X, Zhou M, Zhang Y, Dai F, et al. Functional loss of Bmsei causes thermosensitive epilepsy in contractile mutant silkworm, Bombyx mori. Sci Rep. 2015;5:12308. https:\/\/doi.org\/10.1038\/srep12308.","journal-title":"Sci Rep"},{"issue":"1","key":"2621_CR62","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5582\/ddt.2016.01011","volume":"10","author":"H Tabunoki","year":"2016","unstructured":"Tabunoki H, Bono H, Ito K, Yokoyama T. Can the silkworm (Bombyx mori) be used as a human disease model? Drug Discov Ther. 2016;10(1):3\u20138. https:\/\/doi.org\/10.5582\/ddt.2016.01011.","journal-title":"Drug Discov Ther"},{"issue":"7","key":"2621_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0069130","volume":"8","author":"H Tabunoki","year":"2013","unstructured":"Tabunoki H, Ono H, Ode H, Ishikawa K, Kawana N, Banno Y, et al. Identification of key uric acid synthesis pathway in a unique mutant silkworm Bombyx mori model of Parkinson\u2019s disease. PLoS One. 2013;8(7):e69130. https:\/\/doi.org\/10.1371\/journal.pone.0069130.","journal-title":"PLoS One"},{"issue":"9","key":"2621_CR64","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1021\/acs.jproteome.2c00149","volume":"21","author":"F Zhu","year":"2022","unstructured":"Zhu F, Chen H, Han J, Zhou W, Tang Q, Yu Q, et al. Proteomic and targeted metabolomic studies on a silkworm model of Parkinson\u2019s disease. J Proteome Res. 2022;21(9):2114\u201323. https:\/\/doi.org\/10.1021\/acs.jproteome.2c00149.","journal-title":"J Proteome Res"},{"issue":"5","key":"2621_CR65","doi-asserted-by":"publisher","first-page":"489","DOI":"10.2174\/138161211795164095","volume":"17","author":"RD Prediger","year":"2011","unstructured":"Prediger RD, Aguiar AS Jr, Moreira EL, Matheus FC, Castro AA, Walz R, et al. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson\u2019s disease. Curr Pharm Des. 2011;17(5):489\u2013507. https:\/\/doi.org\/10.2174\/138161211795164095.","journal-title":"Curr Pharm Des"},{"issue":"S3","key":"2621_CR66","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1002\/ana.10483","volume":"53","author":"P Jenner","year":"2003","unstructured":"Jenner P. Oxidative stress in Parkinson\u2019s disease. Ann Neurol. 2003;53(S3):S26\u201336. https:\/\/doi.org\/10.1002\/ana.10483.","journal-title":"Ann Neurol"},{"key":"2621_CR67","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1146\/annurev-pathol-011110-130242","volume":"6","author":"JM Shulman","year":"2011","unstructured":"Shulman JM, De Jager PL, Feany MB. Parkinson\u2019s disease: genetics and pathogenesis. Annu Rev Pathol. 2011;6:193\u2013222. https:\/\/doi.org\/10.1146\/annurev-pathol-011110-130242.","journal-title":"Annu Rev Pathol"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02621-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-022-02621-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02621-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T20:08:23Z","timestamp":1666901303000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-022-02621-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2621"],"URL":"https:\/\/doi.org\/10.1186\/s12916-022-02621-9","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,28]]},"assertion":[{"value":"5 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"412"}}